Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Last Updated   April 26, 2025

Want to learn how to participate in this trial?

90014496LYM1001

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    18+ years
  • Phase
    phase 1
    1
  • Sites
    26 Sites
  • Status
    Recruiting

SUMMARY

This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non-Hodgkin lymphoma (B-NHL).

CONDITIONS

  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell

ELIGIBILITY


Inclusion Criteria:

* Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent
* Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
* Must meet the following indications for each subtype: Relapsed or refractory mature aggressive large B cell non-Hodgkin lymphoma (NHL) and follicular lymphoma Grade 3b: Participants must have had >= 2 lines of systemic therapy or >= 1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT); Relapsed or refractory follicular lymphoma Grade 1-3a and marginal zone lymphoma: Participants must have had >= 2 prior lines of anti-neoplastic systemic therapy. Participants also must have prior exposure to an anti-CD20 monoclonal antibody
* Frontline high-risk diffuse large B Cell lymphoma (DLBCL): Participants must have DLBCL or high-grade B-cell lymphoma (HGBCL) with residual lymphoma by positive interim positron emission computed tomography 2 or 3 cycles of frontline chemoimmunotherapy. Participants must have only received 2 or 3 cycles of frontline chemoimmunotherapy for DLBCL
* Measurable disease as defined by Lugano 2014 classification
* Eastern cooperative oncology group (ECOG) performance status of either 0 or 1. ECOG of 0 to 2 is allowed in frontline high-risk DLBCL cohort


Exclusion Criteria:

* Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell/histiocyte-rich large B-cell lymphoma
* Any prior solid organ or allogeneic stem cell transplantation
* Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion
* Uncontrolled active infections
* History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT])
* History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening
* History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder
* Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
* Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)


Inclusion Criteria:

* Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent
* Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
* Must meet the following indications for each subty

More...

DETAILS

LOCATIONS

Locations in:
United States, Australia, Denmark, Netherlands, Spain, United Kingdom, Canada, South Korea
Country (8) City or Province (26) Status
United States Duarte City of Hope
RECRUITING
United States Denver Colorado Blood Cancer Institute
RECRUITING
United States Piscataway Rutgers Cancer Institute of New Jersey
RECRUITING
United States Charlotte Levine Cancer Institute
RECRUITING
United States Pittsburgh University of Pittsburgh Medical Center
RECRUITING
United States Austin St. David's South Austin Medical Center
RECRUITING
United States San Antonio Texas Transplant Institute
RECRUITING
United States Seattle Swedish Cancer Institute
RECRUITING
Australia Fitzroy St Vincents Hospital Melbourne
RECRUITING
Australia Melbourne The Alfred Hospital
RECRUITING
Australia Murdoch Fiona Stanley Hospital
RECRUITING
Australia Waratah Calvary Mater Newcastle Hospital
RECRUITING
Denmark Copenhagen Rigshospitalet
RECRUITING
Denmark Odense Odense University Hospital
RECRUITING
Netherlands Utrecht UMC Utrecht
RECRUITING
Spain Barcelona Hosp Clinic de Barcelona
RECRUITING
United Kingdom London University College London Hospitals
RECRUITING
United States Iowa City University of Iowa Hospital and Clinics
RECRUITING
Canada Toronto Princess Margaret Cancer Centre University Health Network
RECRUITING
South Korea Seoul Seoul National University Hospital
RECRUITING
South Korea Seoul Asan Medical Center
RECRUITING
South Korea Seoul Samsung Medical Center
RECRUITING
Netherlands Rotterdam Erasmus MC
RECRUITING
Spain Barcelona Hosp Univ Vall D Hebron
RECRUITING
Spain Madrid Hosp Univ Fund Jimenez Diaz
RECRUITING
United Kingdom Manchester The Christie NHS Foundation Trust Christie Hospital
RECRUITING
Show More
Geo Locations

34.13945, -117.97729

39.73915, -104.9847

40.49927, -74.39904

35.22709, -80.84313

40.44062, -79.99589

30.26715, -97.74306

29.42412, -98.49363

47.60621, -122.33207

-37.79839, 144.97833

-37.814, 144.96332

-32.06987, 115.83757

-32.90667, 151.72647

55.67594, 12.56553

55.39594, 10.38831

52.09083, 5.12222

41.38879, 2.15899

51.50853, -0.12574

41.66113, -91.53017

43.70011, -79.4163

37.566, 126.9784

37.566, 126.9784

37.566, 126.9784

51.9225, 4.47917

41.38879, 2.15899

40.4165, -3.70256

53.48095, -2.23743

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.